Funding for this research was provided by:
Ministry of Science and Technology, Taiwan (108-2321-B-010-001 and 108-2321-B-010-014-MY2, 107-2314-B-075-015-MY2-2, 107-2221-E-010-007 and 108-2221-E-010-004)
Taipei Veterans General Hospital (V108C-129 and V107C-091)
Yen Tjing Ling Medical Foundation (CI-109-1)
Received: 27 May 2020
Accepted: 10 November 2020
First Online: 16 November 2020
Ethics approval and consent to participate
: All participants completed informed consent forms after receiving a complete explanation of the study. The Institutional Review Board of Taipei Veterans General Hospital approved the study protocol (VGHTPE-IRB, 2015–10-001 BC).
: Not applicable.
: FJ Hsiao, WT Chen, HY Liu, YF Wang, SP Chen, KL Lai, and LLH Pan declare no potential conflicts of interest. SJ Wang has served on the advisory boards of Eli Lilly, Daiichi-Sankyo, Taiwan Pfizer and Taiwan Norvatis. He has received honoraria as a moderator from Allergan, Pfizer, Eli Lilly, Bayer, and Eisai.